Chimeric toxins

A chimeric toxin comprising protein fragments joined together by peptide bonds, the chimeric toxin comprising, in sequential order, beginning at the amino terminal end of the chimeric toxin,(a) the enzymatically active Fragment A of diphtheria toxin,(b) a first fragment including the cleavage domain 1.sub.1 adjacent the Fragment A of diphtheria toxin,(c) a second fragment comprising at least a portion of the hydrophobic transmembrane region of Fragment B of diphtheria toxin, the second fragment having a deletion of at least 50 diphtheria toxin amino acid residues, the deletion being C-terminal to the portion of the transmembrane region, and the second fragment not including domain 1.sub.2, and(d) a third fragment comprising a portion of a cell-specific polypeptide ligand, the portion including at least a portion of the binding domain of the polypeptide ligand, the portion of the binding domain being effective to cause the chimeric toxin to bind selectively to a predetermined class of cells to be attacked by the enzymatically active Fragment A.

Skip to:  ·  Claims  ·  References Cited  · Patent History  ·  Patent History

Claims

1. A chimeric toxin which binds selectively to a predetermined class of cells comprising protein fragments joined together by peptide bonds, said chimeric toxin comprising, sequentially from N-terminus to C-terminus,

(a) a first fragment consisting of Fragment A of native diphtheria toxin;
(b) a second fragment comprising a portion of Fragment B of native diphtheria toxin which together with said first Fragment A forms the 1.sub.1 domain of native diphtheria toxin, said portion also comprising the hydrophobic transmembrane domain which is amino acids 346-371, said portion excluding the 1.sub.2 domain which is amino acids 461-471, the eukaryotic binding domain which is amino acids 485-535 of native diphtheria toxin, and at least 50 amino acids N-terminal to said eukaryotic binding domain; and
(c) a third fragment comprising at least a portion of the binding domain of a cell-specific polypeptide ligand effective to cause said chimeric toxin to bind selectively to the predetermined class of cells which bear a receptor to said ligand.

2. The chimeric toxin of claim 1, wherein said second fragment excludes at least 80 amino acids N-terminal to said eukaryotic binding domain.

3. The chimeric toxin of claim 1, wherein said second fragment is amino acid residues 194-371 of native diphtheria toxin.

4. The chimeric toxin of claim 1, wherein said fourth fragment comprises a portion of the binding domain of EGF effective to cause said chimeric toxin to bind selectively to the predetermined class of cells which bear a receptor to EGF.

5. The chimeric toxin of claim 1, wherein said fourth fragment comprises EGF.

6. The chimeric toxin of claim 1, wherein said fourth fragment comprises at least a portion of the binding domain of IL-2 effective to cause said chimeric toxin to bind selectively to the predetermined class of cells which bear a receptor to IL-2.

7. The chimeric toxin of claim 1, wherein said fourth fragment comprises amino acids 2 to 133 of human IL-2.

8. The chimeric toxin of claim 1, wherein said fourth fragment comprises at least a portion of the binding domain of IL-4 effective to cause said chimeric toxin to bind selectively to the predetermined class of cells which bear a receptor to IL-4.

9. The chimeric toxin of claim 1, wherein said fourth fragment comprises IL-4.

10. The chimeric toxin of claim 1, wherein fourth fragment comprises at least a portion of the binding domain of IL-6 effective to cause said chimeric toxin to bind selectively to the predetermined class of cells which bear a receptor to IL-6.

11. The chimeric toxin of claim 1, wherein said fourth fragment comprises IL-6.

12. The chimeric toxin of claim 1, said chimeric toxin possessing any of greater toxicity than that of a toxin comprised of DAB.sub.486 fused to said third fragment, a greater affinity for the receptor on cells of said predetermined class to which said chimeric toxin binds than that of a toxin comprised of DAB.sub.486 fused to said third fragment, greater resistance to proteolytic degradation than that exhibited by a toxin comprised of DAB.sub.486 fused to said third fragment, the ability to inhibit protein synthesis to a given degree by a period of exposure that is shorter than the period of exposure required by DAB.sub.489 fused to said third fragment to inhibit protein synthesis to the same degree, or the ability to effect a more rapid onset of the inhibition of protein synthesis than that exhibited by DAB.sub.486 fused to said third fragment.

13. The chimeric toxin of claim 1, which is at least about four times as cytotoxic to said predetermined class of cells than DAB.sub.486 fused to said third fragment.

14. The chimeric toxin of claim 1, which is at least about ten times as cytotoxic to said predetermined class of cells than DAB.sub.486 fused to said third fragment.

Referenced Cited
U.S. Patent Documents
4468382 August 28, 1984 Bacha
4675382 June 23, 1987 Murphy
4830962 May 16, 1989 Gelfand et al.
Foreign Patent Documents
259904 March 1988 EPX
332174 September 1989 EPX
8503508 September 1985 WOX
8702987 May 1987 WOX
9119745 December 1991 WOX
Other references
  • Edwards, et al., Mol. Cell Biol. 9(7):2860-67 (1989). Lambotte, et al., J. Cell Biol. 87:837-40 (1980). Colombatti, et al., J. Biol. Chem. 261(7):3030-35 (1986). Greenfield, et al., PNAS USA 80:6853-57 (1983). Boguet, et al., PNAS USA 73:4449-53 (1976). Bacha, et al., J. Biol. Chem. 258(3):1565-70 (1983). Cabiaux, et al., J. Biol. Chem. 264(9):4928-38 (1989). Rappuoli, et al., J. Bacteriol. 153:1202-10 (1983). Bacha, et al., J. Exp. Med. 167: 612-22 (1988). Williams, et al., in Protein Engineering 1:493-98 (1987). Bishai, et al., J. Bacteriol. 169(4):1554-63 (1987). D. Williams, et al., "Structure/Function Analysis of IL-2 Toxin," in Protein Society Meeting, Aug. 1989. Greenfield, et al., Science 238:536-39 (1987). Simpson, et al., Cell 29:469-473 (1982).
Patent History
Patent number: 5763250
Type: Grant
Filed: Jun 7, 1995
Date of Patent: Jun 9, 1998
Assignee: Boston Medical Center Corporation (Boston, MA)
Inventors: Diane Williams (Franklin, MA), John R. Murphy (Boston, MA)
Primary Examiner: Karen Carlson
Law Firm: Lerner, David, Littenberg, Krumholz & Mentlik
Application Number: 8/479,107